Decyl dimethyl-2-hydroxyethylammonium chloride | 28228-56-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Decyl dimethyl-2-hydroxyethylammonium chloride
• 英文别名: decyl dimethyl hydroxyethyl ammonium chloride；Decyl-(2-hydroxyethyl)-dimethylazanium;chloride
• CAS: 28228-56-0
• 化学式: C₁₄H₃₂NO*Cl
• 分子量: 265.867
• InChiKey: RLGGVUPWOJOQHP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Decyl dimethyl-2-hydroxyethylammonium chloride 、 乙酰氯 、 disodium;carbonate 生成 decyl dimethyl 2-acetyloxyethyl ammonium chloride
  参考文献：
  名称：

  SMITH, KIM R.;BORLAND, JAMES E.;SAUER, JOE D.

  摘要：

  DOI：
• 作为产物：
  描述：

  癸叔胺 、 2-氯乙醇 、 乙酸乙酯 生成 Decyl dimethyl-2-hydroxyethylammonium chloride
  参考文献：
  名称：

  SMITH, KIM R.;BORLAND, JAMES E.;SAUER, JOE D.

  摘要：

  DOI：

文献信息

• FLUORESCENCE DETECTION OF POISON OAK OIL
  申请人：The Regents of the University of California

  公开号：US20130121924A1

  公开（公告）日：2013-05-16

  The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.

  本公开的发明提供了用于合成所述组合物的方法，以及使用所述组合物的方法，其中这些组合物和方法可用于结合和/或使毒橡树油（如漆酚）失活。这些组合物和方法可用于治疗和/或减轻对毒橡树、毒藤、毒漆树、芒果、漆树和腰果中发现的天然化合物的炎症反应和/或过敏反应。
• COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN
  申请人：Kipp E. James

  公开号：US20070111965A1

  公开（公告）日：2007-05-17

  The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

  本发明涉及含脂氧化酶抑制剂和环糊精的包含物复合物的配方，具有治疗有效浓度的脂氧化酶抑制剂，制备方法以及使用它们治疗疾病状态的方法。形成环糊精复合物可以增强脂氧化酶抑制剂的水溶性，从而允许在溶液中获得更高浓度的脂氧化酶。脂氧化酶抑制剂-环糊精复合物的水溶性配方适用于静脉或口服给药，用于治疗和/或预防炎症性疾病状态。水溶性配方可以冻干以延长储存稳定性，帮助口服给药和/或提供方便和经济的包装。
• COMPOSITIONS OF LIPOXYGENASE INHIBITORS
  申请人：Kipp E. James

  公开号：US20070134341A1

  公开（公告）日：2007-06-14

  Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

  提供了包含脂氧合酶抑制剂化合物颗粒的制药组合物，其有效平均尺寸从大约10纳米到大约50微米。更具体地，提供了有效平均尺寸从大约50纳米到大约5微米的5-脂氧合酶抑制剂化合物颗粒的制药组合物。这些制药组合物以水悬浮液的形式存在，其中5-脂氧合酶抑制剂化合物的颗粒浓度为大约5到200毫克/毫升。此外，还提供了制备这种制药组合物的方法。具体来说，揭示了使用至少一种表面活性剂进行微相沉淀和直接均质化制备制药组合物的方法。
• Colorless Transparent Polyimide Composite Film and Method for Producing Same
  申请人：Makinoshima Takashi

  公开号：US20080020217A1

  公开（公告）日：2008-01-24

  The present invention provides a colorless, transparent polyimide composite film containing a polyimide (A) having a specific repeating unit, and an organic-treated layered silicate (B) obtained through treatment with an organic onium ion having a specific structure such that the organic-treated layered silicate (B) is dispersed in the polyimide (A); and as well a method for producing a colorless, transparent polyimide composite film, the method including forming a film-form mixture through extrusion or application, onto a support, of a three-component liquid mixture containing the polyimide (A), the organic-treated layered silicate (B), and an organic solvent (C) having a specific SP value; and subsequently removing the organic solvent (C) from the film-form mixture. The polyimide composite film of the present invention is a colorless, transparent film containing the polyimide (A) and the organic-treated layered silicate (B) which is very uniformly dispersed in the polyimide, exhibiting excellent heat resistance and mechanical properties, and exhibiting flexibility.

  本发明提供了一种无色透明的聚酰亚胺复合膜，其中包含具有特定重复单元的聚酰亚胺（A）和经有机阳离子处理的具有特定结构的有机处理层状硅酸盐（B），使得经有机处理的层状硅酸盐（B）分散在聚酰亚胺（A）中；以及一种生产无色透明聚酰亚胺复合膜的方法，该方法包括通过挤出或应用形成膜形混合物，将聚酰亚胺（A）、经有机处理的层状硅酸盐（B）和具有特定SP值的有机溶剂（C）的三组分液体混合物涂覆到支撑物上，并随后从膜形混合物中去除有机溶剂（C）。本发明的聚酰亚胺复合膜是一种无色透明的膜，其中包含聚酰亚胺（A）和经有机处理的层状硅酸盐（B），后者在聚酰亚胺中非常均匀地分散，具有优异的耐热性和机械性能，同时还具有柔韧性。
• Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
  申请人：Babul Najib

  公开号：US20120065221A1

  公开（公告）日：2012-03-15

  The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.

  本发明涉及口服、治疗有效的3-羟基-N-甲基吗啡酮的延迟作用、延长释放药物组成物，包括延迟起效、延长释放剂型及其使用。